CelluTarget · Multifocal Motor Neuropathy · Clinical Trials
Phase 2
Active (not recruiting)
NCT05358717

Votoplam (PTC518)

Sponsored by PTC Therapeutics ↗
View on ClinicalTrials.gov ↗
Timeline
Study Dates
Start Date
May 2022
Est. Completion
June 2027
Enrollment Target
106 participants
Status
Active (not recruiting)
Study Design
Primary Endpoint
Safety, tolerability, and reduction in huntingtin protein levels across PTC518 dose cohorts
Registry
ClinicalTrials.gov Record
Registry ID
NCT05358717
Direct Link
clinicaltrials.gov/NCT05358717 ↗
Related Treatment
Treatment Being Studied
Votoplam (PTC518) →